Drug Profile
Research programme: anti-PcrV and anti-PcrV/Psl monoclonal antibodies - AstraZeneca
Alternative Names: 166; MS1; MS2; MS3Latest Information Update: 09 Dec 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Bacterial polysaccharide inhibitors; PcrV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pseudomonal-infections(Prevention) in USA (Parenteral)
- 12 Sep 2012 Pharmacodynamics data from preclinical trials in Pseudomonal infections presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
- 12 Sep 2012 Preclinical trials in Pseudomonal infections (prevention) in USA (Parenteral)